Clinical Commander

Back to dossier
cardio.stemi.antiphospholipid-syndrome-related.v1PRODUCTION
cardio.stemi.antiphospholipid-syndrome-related.v1

STEMI — antiphospholipid syndrome related (arterial APS thrombosis)

cardiologyacuteadult
Hard-required inputs
0 / 6
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

STEMI in patient with known APS or thrombosis pattern raising APS suspicion; coronary thrombosis (often more thrombus than plaque) is presenting feature

Inputs
1
Actions
0
Advance rule
Set
Advance when

STEMI confirmed + APS suspicion or prior dx noted

Patient inputs (9)

Younger STEMI patients (<50) with thrombosis history raise APS suspicion

Contrast nephropathy + warfarin/DOAC dosing

STEMI territory localization; identical to parent

Infarct sizing + serial trend

Hemodynamic stratification + shock screen

May show fresh thrombus disproportionate to plaque; aspiration thrombectomy may be useful adjunct in this subset

APS criterion lab — must be drawn BEFORE heparin/warfarin (heparin invalidates LA assay) OR repeat ≥12 wk after AC washout

IgG + IgM aCL ≥40 GPL/MPL or >99th percentile on 2 occasions ≥12 wk apart per Sydney criteria

IgG + IgM β2-GPI >99th percentile on 2 occasions ≥12 wk apart per Sydney criteria

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningcatastrophic_aps_multi_organ_thrombosis
    Multi-organ thrombosis (≥3 organs) in <1 wk in known/suspect APS — Catastrophic APS (CAPS); mortality 50% without aggressive triple therapy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredoac_exposure_error_in_known_aps
    Patient with known APS placed on DOAC (rivaroxaban/apixaban/edoxaban) for AC — TRAPS showed inferior outcomes vs warfarin in arterial APS subset
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepregnancy_in_aps_with_prior_arterial_event
    Patient with prior APS-related arterial event (STEMI) becomes pregnant — warfarin teratogenic + fetal hemorrhage; need LMWH + ASA bridge
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_thrombosis_on_therapeutic_warfarin
    Recurrent arterial or venous thrombosis despite documented therapeutic INR 2.5-3.5 — APS treatment failure
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives risk stratification
Loading…

Recommended regimen

APS-related STEMI long-term anticoagulation — WARFARIN preferred (NOT DOAC) per TRAPS arterial subset
axis: aps_stemi_anticoagulation_phenotype
Selected axis "APS-related STEMI long-term anticoagulation — WARFARIN preferred (NOT DOAC) per TRAPS arterial subset" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    162-325 mg chewed → 81 mg daily LIFELONG • PO • load + daily LIFELONG
    triggers: stemi_acute
    AHA 2025 Class I acute + EULAR 2019 APS Class I lifelong concurrent ASA with warfarin in arterial APS
    rxcui 243670
  • ticagrelor
    first line
    p2y12_inhibitor
    180 mg load → 90 mg BID × 12 mo • PO • BID × 12 mo DAPT
    triggers: stemi_pci_planned
    PLATO PMID 19717846; standard ACS DAPT applies to APS-STEMI
    rxcui 1116632
  • heparin_unfractionated
    first line
    parenteral_anticoagulant
    70-100 U/kg IV bolus then infusion to aPTT 1.5-2.5×control • IV • bolus + infusion
    triggers: stemi_pci, bridge_to_warfarin
    AHA 2025 Class I; UFH preferred over LMWH in APS for monitoring (anti-Xa more reliable than aPTT if LA prolongs baseline)
    rxcui 5224
  • warfarin
    first line
    vitamin_k_antagonist
    5 mg daily; INR target 2.5-3.5 (HIGHER target for arterial APS vs 2-3 venous) • PO • daily LIFELONG
    triggers: confirmed_aps_arterial_thrombosis, triple_positive_aps
    EULAR 2019 APS Class I; ASH 2018 (PMID 30482764); arterial APS — INR 2.5-3.5; LIFELONG (no taper); NEVER interrupt without bridge — interruption is leading APS thrombosis trigger
    rxcui 11289
  • atorvastatin
    first line
    statin
    80 mg daily • PO • daily
    triggers: stemi_secondary_prevention
    PROVE-IT PMID 15007110; pleiotropic anti-inflammatory effect may also benefit APS endothelial dysfunction
    rxcui 83367
  • hydroxychloroquine
    comorbidity specific
    antimalarial_dmard
    200-400 mg daily (≤5 mg/kg ideal weight) • PO • daily
    triggers: sle_overlap_aps, recurrent_thrombosis_on_warfarin
    EULAR 2019 weak recommendation — HCQ reduces APS thrombosis risk especially with SLE overlap; consider in refractory/recurrent disease
    rxcui 5521

outpatient playbook — drug actions (3)

  1. 1. lifelong warfarin INR 2.5-3.5
    rxcui 11289
    titrate • PO • daily LIFELONG
    trigger: APS arterial thrombosis
    EULAR 2019 + ASH 2018 — no taper, no DOAC switch (TRAPS PMID 30196097)
  2. 2. lifelong ASA 81 mg
    rxcui 243670
    81 mg daily • PO • daily LIFELONG
    trigger: concurrent ASA in arterial APS post-STEMI
    EULAR 2019
  3. 3. consider HCQ adjunct
    rxcui 5521
    200-400 mg daily • PO • daily
    trigger: SLE overlap or refractory APS
    EULAR 2019 weak recommendation

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: ST elevation on ECG in patient with known APS or triple-positive antibody profile; STEMI in young patient (<50) with prior venous thrombosis or pregnancy losses → APS suspect; Coronary cath shows thrombus burden disproportionate to atherosclerotic plaque → thrombophilia workup.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**STEMI — antiphospholipid syndrome related (arterial APS thrombosis)** (cardio.stemi.antiphospholipid-syndrome-related.v1).
Scope: STEMI in patient with known APS or thrombosis pattern raising APS suspicion; coronary thrombosis (often more thrombus than plaque) is presenting feature

No severity triggers fired against current inputs.

Plan

Regimen axis: **APS-related STEMI long-term anticoagulation — WARFARIN preferred (NOT DOAC) per TRAPS arterial subset**.
1. aspirin 162-325 mg chewed → 81 mg daily LIFELONG PO load + daily LIFELONG (antiplatelet_cox1, first line) — AHA 2025 Class I acute + EULAR 2019 APS Class I lifelong concurrent ASA with warfarin in arterial APS
2. ticagrelor 180 mg load → 90 mg BID × 12 mo PO BID × 12 mo DAPT (p2y12_inhibitor, first line) — PLATO PMID 19717846; standard ACS DAPT applies to APS-STEMI
3. heparin_unfractionated 70-100 U/kg IV bolus then infusion to aPTT 1.5-2.5×control IV bolus + infusion (parenteral_anticoagulant, first line) — AHA 2025 Class I; UFH preferred over LMWH in APS for monitoring (anti-Xa more reliable than aPTT if LA prolongs baseline)
4. warfarin 5 mg daily; INR target 2.5-3.5 (HIGHER target for arterial APS vs 2-3 venous) PO daily LIFELONG (vitamin_k_antagonist, first line) — EULAR 2019 APS Class I; ASH 2018 (PMID 30482764); arterial APS — INR 2.5-3.5; LIFELONG (no taper); NEVER interrupt without bridge — interruption is leading APS thrombosis trigger
5. atorvastatin 80 mg daily PO daily (statin, first line) — PROVE-IT PMID 15007110; pleiotropic anti-inflammatory effect may also benefit APS endothelial dysfunction
6. hydroxychloroquine 200-400 mg daily (≤5 mg/kg ideal weight) PO daily (antimalarial_dmard, comorbidity specific) — EULAR 2019 weak recommendation — HCQ reduces APS thrombosis risk especially with SLE overlap; consider in refractory/recurrent disease

Setting playbook (outpatient) — Lifelong APS management: warfarin INR 2.5-3.5, ASA 81 mg, statin, BB if EF↓; rheumatology + cardiology + hematology multidisciplinary; pregnancy planning if applicable (LMWH + ASA, NEVER warfarin in pregnancy)
7. lifelong warfarin INR 2.5-3.5 titrate PO daily LIFELONG — APS arterial thrombosis (EULAR 2019 + ASH 2018 — no taper, no DOAC switch (TRAPS PMID 30196097))
8. lifelong ASA 81 mg 81 mg daily PO daily LIFELONG — concurrent ASA in arterial APS post-STEMI (EULAR 2019)
9. consider HCQ adjunct 200-400 mg daily PO daily — SLE overlap or refractory APS (EULAR 2019 weak recommendation)

Non-pharmacologic actions:
- Pregnancy planning: LMWH + ASA, hold warfarin (teratogen)
- Avoid estrogen OCP/HRT
- Smoking cessation absolutely critical
- MedicAlert bracelet

AVOID / contraindication checks:
- Rivaroxaban_AVOID_in_triple_positive_aps (TRAPS PMID 30196097 — INFERIOR to warfarin for arterial events)
- Apixaban_AVOID_in_arterial_aps (extrapolated from TRAPS; no DOAC RCT supports use in arterial APS)
- Warfarin_target_INR_2.5 3.5_for_arterial_aps (vs 2 3 venous; EULAR 2019)
- NEVER_interrupt_anticoagulation_without_bridge (interruption = APS thrombosis trigger)
- Avoid_estrogen_OCP_HRT_in_aps (procoagulant, increases thrombosis risk)

Monitoring

Regimen monitoring:
- INR daily during warfarin initiation then q1-2wk then q4wk (target 2.5-3.5)
- anti Xa for UFH monitoring if LA prolongs baseline aPTT (LA invalidates aPTT)
- CBC for thrombocytopenia (APS may have mild thrombocytopenia; HIT screen if heparin)
- serial aps labs at 12 wk to confirm persistence (Sydney criteria require persistence ≥12 wk)

Setting (outpatient) monitoring:
- INR q4wk lifelong
- Annual APS labs + lipid + A1c + creatinine

Follow-up plan: Cardiology + rheumatology + hematology multidisciplinary follow-up; lifelong warfarin INR 2.5-3.5 + ASA; hydroxychloroquine if SLE overlap (may reduce APS thrombosis); avoid OCPs/HRT (estrogen worsens APS)
- Close-out criterion: multidisciplinary plan + AC adherence pathway booked

Monitoring phase: Serial troponin, telemetry, INR daily during warfarin initiation (target 2.5-3.5 for arterial APS), reinforce LIFELONG AC + adherence (interruption = thrombosis trigger)

Disposition

Current setting: outpatient — Lifelong APS management: warfarin INR 2.5-3.5, ASA 81 mg, statin, BB if EF↓; rheumatology + cardiology + hematology multidisciplinary; pregnancy planning if applicable (LMWH + ASA, NEVER warfarin in pregnancy)

Disposition criteria:
- Long-term continuation; cross-link to chronic ASCVD + rheumatology engines

Escalation triggers (move to higher acuity):
- Recurrent thrombosis → escalate AC intensity, add HCQ, consider rituximab (refractory CAPS)
- Pregnancy → switch to LMWH + ASA immediately, rheumatology + MFM consult

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Multi-organ thrombosis (≥3 organs) in <1 wk in known/suspect APS — Catastrophic APS (CAPS); mortality 50% without aggressive triple therapy
- [SEVERE] Patient with known APS placed on DOAC (rivaroxaban/apixaban/edoxaban) for AC — TRAPS showed inferior outcomes vs warfarin in arterial APS subset
- [SEVERE] Patient with prior APS-related arterial event (STEMI) becomes pregnant — warfarin teratogenic + fetal hemorrhage; need LMWH + ASA bridge

Citations

- 2025 ACC/AHA ACS + ESC 2023 ACS + EULAR 2019 APS Management + ASH 2018 Thrombophilia [PMID:37622670](https://pubmed.ncbi.nlm.nih.gov/37622670/)
- Cited evidence (PMID 30482764) [PMID:30482764](https://pubmed.ncbi.nlm.nih.gov/30482764/)
- Cited evidence (PMID 30196097) [PMID:30196097](https://pubmed.ncbi.nlm.nih.gov/30196097/)
- Cited evidence (PMID 27932287) [PMID:27932287](https://pubmed.ncbi.nlm.nih.gov/27932287/)
- Cited evidence (PMID 29562136) [PMID:29562136](https://pubmed.ncbi.nlm.nih.gov/29562136/)

Last reconciled with current guidelines: 2026-05-15.
References